Mazidi, Mohsen, Karimi, Ehsan, Rezaie, Peyman and Ferns, Gordon A (2016) Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications. ISSN 1056-8727
![]() |
PDF
- Accepted Version
Available under License Creative Commons Attribution-NonCommercial No Derivatives. Download (1MB) |
Abstract
Aim: To undertake a systematic review and meta-analysis of randomized controlled trials of the effect of Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) therapy on serum C-reactive protein (CRP) concentrations.
Method: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched for the period up until March 16 2016. Prospective studies evaluating the impact of GLP-1 RAs on serum CRP were identified. A random effects model (using the DerSimonian-Laird method) and generic inverse variance methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I2 index. Random effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of potential moderator.
International Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868.
Results: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD –2.14 (mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%). Removal of one study in the meta-analysis did not change the result in the sensitivity analysis (WMD –2.14(mg/dL), 95% CI -3.51, –0.78, P=0.002; I2 96.1%), indicating that our results could not be solely attributed to the effect of a single study. Random effects meta-regression was performed to evaluate the impact of potential moderator on the estimated effect size. Changes in serum CRP concentration were associated with the duration of treatment (slope –0.097, 95% CI –0.158, -0.042, P<0.001).
Conclusions: This meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP.
Item Type: | Article |
---|---|
Keywords: | meta-analysis Glucagon-like peptide-1 receptor agonist C-reactive protein |
Schools and Departments: | Brighton and Sussex Medical School > Division of Medical Education |
Subjects: | R Medicine |
Depositing User: | Elizabeth Morris |
Date Deposited: | 02 Jun 2016 09:19 |
Last Modified: | 02 Jun 2017 07:29 |
URI: | http://srodev.sussex.ac.uk/id/eprint/61270 |
View download statistics for this item
📧 Request an update